

10692 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

81. Huffman, D. H. and D. L. Azarnoff, "Absorption of Orally Given Digoxin Preparations," Journal of the American Medical Association, 222, No. 8:957-960, 1972.
82. Meade, R. C. and T. J. Kleist, "Improved Radioimmunoassay of Digoxin and Other Sterol-like Compounds Using Somogyi Precipitation," Journal of Laboratory and Clinical Medicine, 80:748-754, 1972.
83. Hobson, J. D. and A. Zettner, "Digoxin Serum Half-life Following Suicidal Digoxin Poisoning," Journal of the American Medical Association, 223, No. 2:147-149, 1973.
84. Smith, T. W., "Digitalis Glycosides (First of Two Parts)," New England Journal of Medicine, 228, No. 14:719-722, 1973.
85. Sorby, D. L. and T. N. Tozer, "On the Evaluation of Biologic Availability of Digoxin from Tablets," Drug Intelligence and Clinical Pharmacology, 7:78-83, 1973.
86. Burnett, G. H., R. L. Conklin, G. W. Wasson and A. A. MacKinney, "Variability of Standard Curves in Radioimmunoassay of Plasma Digoxin," Clinical Chemistry, 19, No. 7:725-726, 1973.
87. Vieweg, W. V. R. and J. Sode, "Evaluation of Biologic Availability of Digoxin Preparations Available to a Naval Hospital," Medical Annals of the District of Columbia, 42, No. 3:136-140, 1973.
88. Skelly, J. P. and G. Knapp, "Biologic Availability of Digoxin Tablets," Journal of the American Medical Association (editorial), 224, No. 2:243, 1973.